

# NANOSPACE

Small Scale, Big Impact

---


**Revolutionizing virus detection with advanced nanobiosensors**



# Problem


- Traditional methods lack the accuracy and speed to monitor our gut's viral entities effectively.
- With gut health playing a crucial role in our overall well-being, this knowledge gap hinders our ability to combat prevalent gut diseases.

Among 254 people surveyed:  
People with gut health problems



With problems  
Without problems  
Not sure


The impact of gut health problems  
on people's everyday lives





Moderate impact  
Slight impact  
Strong impact  
Low Impact

# Solution


- NanoSpace is advancing a unique technology that merges molecularly imprinted polymers and aptamers with Carbon nanotube sensors, and a microfluidic platform for rapid, accurate virome detection.
- Simultaneously, we're developing artificial intelligence software to analyze the virome data, aiming to predict potential gut diseases. This approach is set to redefine the landscape of medical diagnostics and prevention.




# Ideas of the nanosensor



**MIP = Trap**



**Aptamer = Fishing rod**




Research about MIP

- A - the overall device layout with parallel microfluidic channels;
- B - the integration of MIPs and aptamers with CNT-FET sensors;
- C - the MIP-functionalized CNT sensor process;
- D - the aptamer-functionalized CNT sensor process.

Base research about aptamers link

# Nanobiosensors Market



- Our main target is the medical diagnostics sector, which is the largest segment in the nanobiosensor market.
- Within this market, the medical diagnostics sector presents the most significant opportunity, and that's where we aim to focus our efforts.
- Our technology is well-positioned to meet the needs of this rapidly expanding market.

## Main players




# Product overview & Revenue model

Our future product is a nanoscale biosensor device with a disposable sensor cartridge for each test.

The biosensor will offer real-time detection, and its nanoscale technology will enable scalability and adaptability for a broader range of viral targets.

Once our product is fully developed, we anticipate two revenue streams.

- 1) upfront sale of our nanoscale biosensor device;
- 2) recurring revenue from the sale of sensor cartridges.







# Go-to-market strategy

Our go-to-market strategy is to initially target key stakeholders in the medical diagnostics industry, including **hospitals, clinics, and research institutions**. We will engage these stakeholders through direct sales, partnerships, and strategic alliances.

Among 61 people from healthcare surveyed:

The interest of healthcare professionals in a our devise





**NANOSPACE**

Small Scale, Big Impact

# Our team

**Maryna Tselishcheva**  
Co-CEO & co-founder  
Doctor  
+380950995222  
tselishchevamaryna@gmail.com

**Bohdan Vodianyuk**  
Co-CEO & co-founder  
Biomedical electronic engineer  
+380660042119  
bohdanvodianyuk@gmail.com





# Our advisors



**Maria Luisa Antequera Gomez**  
PhD in Cellular and molecular biology  
Professor at the University of Málaga (Universidad de Málaga) and Researcher at KHAOS Research, Instituto de Tecnología e Ingeniería del Software “Jose María Troya Linero” (ITIS)




UNIVERSIDAD DE MÁLAGA

**Ismael Navas Delgado**  
PhD in Informática  
Professor at the University of Málaga (Universidad de Málaga) and Researcher at KHAOS Research, Instituto de Tecnología e Ingeniería del Software “Jose María Troya Linero” (ITIS)




**Anton Popov**  
PhD in Biomedical Devices and Systems  
Associate Professor of Electronic Engineering  
Department of Faculty of Electronics at the National Technical University of Ukraine  
“Igor Sikorsky Kyiv Polytechnic Institute”



**NANOSPACE**  
Small Scale, Big Impact

# Questions & Answers





**NANOSPACE**  
Small Scale, Big Impact



**Thank you for your attention!**